{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:51:22Z","timestamp":1791960682844,"version":"4.3.4"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1097\/icb.0b013e3182a48bcc","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T17:11:35Z","timestamp":1377882695000},"page":"24-29","source":"Crossref","is-referenced-by-count":10,"title":["INTRAVITREAL ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION IN OCULAR HISTOPLASMOSIS"],"prefix":"10.1097","volume":"8","author":[{"given":"Jennifer","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan V.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210126","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archopht.1987.01060110045029","article-title":"Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. Results of a randomized clinical trial.","volume":"105","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"R2-8-20210126","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(02)01103-X","article-title":"; Verteporfin in Ocular Histoplasmosis (VOH) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.","volume":"109","author":"Saperstein","year":"2002","journal-title":"Ophthalmology"},{"key":"R3-8-20210126","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":". Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R4-8-20210126","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":". Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"R6-8-20210126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":". Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R7-8-20210126","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Group; Martin DF, Maguire MG, Ying GS, et al.. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-8-20210126","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2007.12.030","article-title":". Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.","volume":"145","author":"Schadlu","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R9-8-20210126","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ophtha.2011.08.032","article-title":". Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.","volume":"119","author":"Cionni","year":"2012","journal-title":"Ophthalmology"},{"key":"R10-8-20210126","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0b013e318229b220","article-title":". Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.","volume":"32","author":"Nielsen","year":"2012","journal-title":"Retina"},{"key":"R11-8-20210126","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":". An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"}],"container-title":["RETINAL Cases &amp; Brief Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICB.0b013e3182a48bcc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T06:24:46Z","timestamp":1646461486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01271216-201400810-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/icb.0b013e3182a48bcc","relation":{},"ISSN":["1935-1089"],"issn-type":[{"value":"1935-1089","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}